2016 BMC cancer

With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study.

, , , , , , , , , (+7 more)

BMC cancer Vol. 16 (1) : 774 • Oct 2016

BACKGROUND: The study aimed to evaluate the long-term outcome in patients with advanced local recurrent nasopharyngeal carcinoma (NPC) treated with or without reirradiation. METHODS: A total of 44 patients treated without reirradiation (non-RT + chemotherapy) were matched with 44 patients treated with reirradiation (re-RT+/-chemtherapy) by age, sex, Karnosky performance score (KPS), rT stage, rN stage, and time interval between initial radiation and recurrence (TI). Overall survival (OS) rate and time to progression (TTP) rate were assessed using Kaplan-Meier method, log-rank test, and Cox regression analysis. RESULTS: From March 2008 to December 2013, a total of 88 well-balanced rT3-4 N0-1 NPC patients were retrospectively analyzed. After a median follow-up of 27 months (range: 6-85), the 5-year OS rate and TTP rate was 23.4 %, 39.0 % in the non-RT + chemotherapy group and 27.5 %, 49.8 % in the re-RT+/-chemtherapy group, respectively. Multivariate analysis showed that significant toxic effect was the only significant prognosticator correlated with OS (HR: 2.15, 95 % CI = 1.02-4.53, p = 0.044). No statistically significant survival differences were observed between the two treatment groups in either univariate or multivariate analyses. CONCLUSION: Compared with reiradiation, treating advanced local recurrent NPC with chemotherapy alone warrants further validation in the view of its similar survival and more acceptable toxicities.

No clinical trial protocols linked to this paper

Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.
PICO Elements

No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.

Paper Details
MeSH Terms
+9 more
Associated Data

No associated datasets or code repositories found for this paper.

Related Papers

Related paper suggestions will be available in future updates.